Multiple clinical trials have shown that the peroxisome proliferator-activated receptor (PPAR)γ agonist pioglitazone and the Glucagon-like peptide-1 (GLP-1) agonist exenatide can improve hepatic steatosis and liver fibrosis, but the main populations included were T2DM patients with NASH (Harrison et al., 2023; Liu et al., 2020). The gene discussed is GCG; the disease is Hepatic fibrosis.